Masaya Nishino

Sakai, 5900197, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 44 publications

Refining Surgical Standards: The Role of Robotic-Assisted Segmentectomy in Early-Stage Non-Small-Cell Lung Cancer.

Refining Surgical Standards: The Role of Robotic-Assisted Segmentectomy in Early-Stage Non-Small-Cell Lung Cancer.

Journal: Cancers

Published: October 23, 2025

Staple Formations in Bronchial Closure with Equal-Height Staples to Those with Graduated-Height Staples Using Motorized Staplers.

Staple Formations in Bronchial Closure with Equal-Height Staples to Those with Graduated-Height Staples Using Motorized Staplers.

Journal: Annals of thoracic and cardiovascular surgery : official journal of the Association of Thoracic and Cardiovascular Surgeons of Asia

Published: June 22, 2025

The Hisashi technique: Making a "pent roof" for safe and curative lung segmentectomy.

The Hisashi technique: Making a "pent roof" for safe and curative lung segmentectomy.

Journal: JTCVS techniques

Published: March 19, 2025

Secondary Mutations of the EGFR Gene That Confer Resistance to Mobocertinib in EGFR Exon 20 Insertion.

Secondary Mutations of the EGFR Gene That Confer Resistance to Mobocertinib in EGFR Exon 20 Insertion.

Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

Published: May 21, 2023

Clinical Relevance of Patient-Derived Organoid of Surgically Resected Lung Cancer as an In Vitro Model for Biomarker and Drug Testing.

Clinical Relevance of Patient-Derived Organoid of Surgically Resected Lung Cancer as an In Vitro Model for Biomarker and Drug Testing.

Journal: JTO clinical and research reports

Published: May 14, 2023

Presence of a Ground-Glass Opacity Component Is the True Prognostic Determinant in Clinical Stage I NSCLC.

Presence of a Ground-Glass Opacity Component Is the True Prognostic Determinant in Clinical Stage I NSCLC.

Journal: JTO clinical and research reports

Published: January 27, 2022

In vitro validation study of HER2 and HER4 mutations identified in an ad hoc secondary analysis of the LUX-Lung 8 randomized clinical trial.

In vitro validation study of HER2 and HER4 mutations identified in an ad hoc secondary analysis of the LUX-Lung 8 randomized clinical trial.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: September 01, 2021

Activity and mechanism of acquired resistance to tarloxotinib in HER2 mutant lung cancer: an in vitro study.

Activity and mechanism of acquired resistance to tarloxotinib in HER2 mutant lung cancer: an in vitro study.

Journal: Translational lung cancer research

Published: March 17, 2021

KRAS Secondary Mutations That Confer Acquired Resistance to KRAS G12C Inhibitors, Sotorasib and Adagrasib, and Overcoming Strategies: Insights From In Vitro Experiments.

KRAS Secondary Mutations That Confer Acquired Resistance to KRAS G12C Inhibitors, Sotorasib and Adagrasib, and Overcoming Strategies: Insights From In Vitro Experiments.

Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

Published: March 03, 2021

Activity of tarloxotinib-E in cells with EGFR exon-20 insertion mutations and mechanisms of acquired resistance.

Activity of tarloxotinib-E in cells with EGFR exon-20 insertion mutations and mechanisms of acquired resistance.

Journal: Thoracic cancer

Published: February 13, 2021

Prognostic implications of preoperative versus postoperative circulating tumor DNA in surgically resected lung cancer patients: a pilot study.

Prognostic implications of preoperative versus postoperative circulating tumor DNA in surgically resected lung cancer patients: a pilot study.

Journal: Translational lung cancer research

Published: November 19, 2020

Dose-dependence in acquisition of drug tolerant phenotype and high RYK expression as a mechanism of osimertinib tolerance in lung cancer.

Dose-dependence in acquisition of drug tolerant phenotype and high RYK expression as a mechanism of osimertinib tolerance in lung cancer.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: October 21, 2020

Showing 1-12 of 44

Last Updated: 09/26/2026